Is endocan a novel potential biomarker of liver steatosis and fibrosis?

BACKGROUND: Studies that evaluated endocan levels in nonalcoholic fatty liver disease (NAFLD) and liver fibrosis are scarce. We aimed to explore endocan levels in relation to different stages of liver diseases, such as NAFLD, as determined with fatty liver index (FLI) and liver fibrosis, as assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Klisić, Aleksandra, Kavarić, Nebojša, Abenavoli, Ludovico, Stanišić, Verica, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, Ninić, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Medical Biochemists of Serbia, Belgrade 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682781/
https://www.ncbi.nlm.nih.gov/pubmed/33269025
http://dx.doi.org/10.2478/jomb-2019-0042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682781/
https://www.ncbi.nlm.nih.gov/pubmed/33269025
http://dx.doi.org/10.2478/jomb-2019-0042

Ejemplares similares